Time to initiation of multidrug-resistant tuberculosis treatment and its relation with outcome in a high incidence district in Lima, Peru

Tropical Medicine and International Health

Volumn 20, Issue 3, 2015, Pages 322-325

  Otero, L ^a,b   De Orbegoso, A ^a   Navarro, A F ^a   Rios J ^c   Parraga T ^a   Gotuzzo, E ^a   Seas, C ^a   Van der Stuyft, P ^b,d  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c Laboratorio Regional   (Peru)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

Multidrug resistant; Peru; Time to treatment; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

DISEASE INCIDENCE; DISEASE TREATMENT; DRUG; SPATIOTEMPORAL ANALYSIS; TUBERCULOSIS;

ADULT; ARTICLE; COLORIMETRY; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PERU; RETROSPECTIVE STUDY; SMEAR; TIME TO TREATMENT; DRUG SUBSTITUTION; FEMALE; INCIDENCE; MALE; OUTCOME ASSESSMENT; STATISTICS AND NUMERICAL DATA; TIME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

LIMA [PERU]; PERU;

ADULT; ANTITUBERCULAR AGENTS; DRUG SUBSTITUTION; FEMALE; HUMANS; INCIDENCE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PERU; RETROSPECTIVE STUDIES; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84922637897     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12430     Document Type: Article

References (11)

1. Clouse K, Page-Shipp L, Dansey H et al. (2012) Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. South African Medical Journal 102, 805-807.
2. Davis JL, Dowdy DW, den Boon S, Walter ND, Katamba A & Cattamanchi A (2012) Test and treat: a new standard for smear-positive tuberculosis. Journal of Acquired Immune Deficiency Syndrome 61, e6-e8.
3. Hanrahan CF, Dorman SE, Erasmus L, Koornhof H, Coetzee G & Golub JE (2012) The impact of expanded testing for multidrug resistant tuberculosis using genotype MTBDRplus in South Africa: an observational cohort study. PLoS One 7, e49898.
4. Jacobson KR, Theron D, Kendall EA et al. (2013) Implementation of GenoType MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clinical Infectious Diseases 56, 503-508.
5. Ministerio de Salud (2010) Estrategia Sanitaria Nacional para la Prevención y Control de la Tuberculosis. Informe Operacional 2012. www.minsa.gob.pe. (accessed 18 June 2013).
6. Orenstein EW, Basu S, Shah NS et al. (2009) Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. The Lancet Infectious Diseases 9, 153-161.
7. Pai NP, Vadnais C, Denkinger C, Engel N & Pai M (2012) Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Medicine 9, e1001306.
8. Shin SS, Yagui M, Ascencios L et al. (2008) Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerging Infectious Diseases 14, 701-708.
9. Theron G, Zijenah L, Chanda D et al. (2014) Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. The Lancet 383, 424-435.
10. World Health Organization (WHO) (2013) World Health Organization Global Report 2013. http://www.who.int/tb/publications/global_report/en/ (accessed 12 January 2014).
11. Yagui M, Perales MT, Asencios L et al. (2006) Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? International Journal Tuberculosis Lung Diseases 10, 838-843.